Eaton Vance Management lessened its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,112,805 shares of the medical research company’s stock after selling 19,510 shares during the quarter. Eaton Vance Management owned 0.17% of Amgen worth $230,673,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the stock. Clarius Group LLC raised its stake in shares of Amgen by 96.4% in the 3rd quarter. Clarius Group LLC now owns 2,471 shares of the medical research company’s stock valued at $512,000 after purchasing an additional 1,213 shares during the period. Marathon Capital Management acquired a new stake in shares of Amgen in the 3rd quarter valued at about $207,000. Bridgeway Capital Management Inc. raised its stake in shares of Amgen by 2.5% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 312,500 shares of the medical research company’s stock valued at $64,778,000 after purchasing an additional 7,500 shares during the period. Logan Capital Management Inc. raised its stake in shares of Amgen by 1.0% in the 3rd quarter. Logan Capital Management Inc. now owns 47,944 shares of the medical research company’s stock valued at $9,938,000 after purchasing an additional 459 shares during the period. Finally, Blair William & Co. IL raised its stake in shares of Amgen by 13.5% in the 3rd quarter. Blair William & Co. IL now owns 102,928 shares of the medical research company’s stock valued at $21,336,000 after purchasing an additional 12,262 shares during the period. 76.94% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now owns 23,090 shares in the company, valued at $4,684,499.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.19% of the stock is owned by company insiders.
Shares of NASDAQ AMGN opened at $191.44 on Friday. The stock has a market capitalization of $126.81 billion, a PE ratio of 15.22, a P/E/G ratio of 2.07 and a beta of 1.41. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.24. The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. Amgen’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $3.27 EPS. As a group, sell-side analysts forecast that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. This is a boost from Amgen’s previous quarterly dividend of $1.32. This represents a $5.80 annualized dividend and a dividend yield of 3.03%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
AMGN has been the topic of several recent research reports. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Monday, October 1st. Mizuho reissued a “buy” rating and issued a $206.00 price target on shares of Amgen in a research note on Friday, October 26th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Amgen in a research note on Thursday, October 25th. Royal Bank of Canada dropped their price target on Amgen to $182.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 31st. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $223.00 price target on shares of Amgen in a research note on Tuesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $205.68.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/amgen-inc-amgn-shares-sold-by-eaton-vance-management.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
See Also: Stock Split
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.